Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Impact of cytostatic compounds on gene expression

ABSTRACT: The cytostatic compounds palbociclib (CDK4/6 inhibitor, 2 uM) and pimasertib (MEK inhibitor, 0.5 uM) were added to the growth media of HT-1080 fibrosarcoma cells for 48 hours. Then, RNA was collected from the samples and sequenced.

ORGANISM(S): Homo sapiens

PROVIDER: GSE180265 | GEO | 2022/01/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

Development of gene expression signatures for subconfluent and overconfluent HT-1080 fibrosarcoma cell line

Project description:We investigated the changes in gene expression profile between subconfluent (80%) and overconfluent HT-1080 fibrosarcoma cell line. We have employed whole genome microarray expression profiling as a discovery platform to identify genes expression profiles in HT-1080 cells. Total RNAs from subconfluent (HT-1080_80%) and overconfluent (HT-1080_overconfluent) HT-1080 cells were harvested and subjected to the microarray analysis.

2015-06-04 | E-GEOD-69534 | biostudies-arrayexpress

RepliSeq of HT-1080 cell line

2014-07-31 | GSE58907 | GEO

Development of gene expression signatures for subconfluent and overconfluent HT-1080 fibrosarcoma cell line

Project description:We investigated the changes in gene expression profile between subconfluent (80%) and overconfluent HT-1080 fibrosarcoma cell line.

2015-06-04 | GSE69534 | GEO

Genes regulated in HT-1080 cells after 24 hours of treatment with IRAK4 inhibitor

Project description:Analysis of HT-1080 fibrosarcoma cells transcriptome following 24 hours treatment with IRAK4 inhibitor was performed. Results provide insight into mode of action of IRAK4 inhibitor under study. Project co-financed from European Regional Development Fund under The Operational Program Innovative Economy, 2007-2013, measure 1.4 (UDA-POIG.01.04.00-12-049/11-00)

2018-11-24 | GSE122845 | GEO

Genes regulated in HT-1080 cells after 4 hours of treatment with IRAK4 inhibitor

Project description:Analysis of HT-1080 fibrosarcoma cells transcriptome following 4 hours treatment with IRAK4 inhibitor was performed. Results provide insight into mode of action of IRAK4 inhibitor under study. Project co-financed from European Regional Development Fund under The Operational Program Innovative Economy, 2007-2013, measure 1.4 (UDA-POIG.01.04.00-12-049/11-00)

2018-11-24 | GSE122844 | GEO

RepliSeq of HT-1080 cell line

Project description:Analysis of replication timing by RepliSeq of HT-1080 Human Connective Tissue Fibrosarcoma Cells. HT-1080 subclone +4 cell line as described in “Human gene targeting favors insertions over deletions.” Russell, D.W., and Hirata, R.K. (2008). Hum Gene Ther 19, 907-914. RepliSeq of HT-1080 cell line was used to determine the impact of DNA replication on targeted adeno-associated virus sites by mapping replication forks, which revealed a consistent preference for recombination at target loci transcribed towards an incoming fork.

2014-07-31 | E-GEOD-58907 | biostudies-arrayexpress

Targets of cytostatic drugs in HT1080 fibrosarcoma

Project description:HT1080 fibrosarcoma cells were treated with cytostatic drugs and analysed on Affymetrix microarray to identify genes and pathways regulated by these compounds. The array images were processed using Affymetrix MAS 5.0 software. and normalized by global scaling or scaled to a polyA+ spike mask Keywords = Cytostatic drugs Keywords = Actinomycin D Keywords = Doxorubicin Keywords = Vincristine Keywords = apoptosis Keywords: ordered

2006-02-04 | GSE2238 | GEO

Transcription profiling of human HT1080 fibrosarcoma cells treated with cytostatic drugs

2008-04-01 | E-GEOD-2238 | biostudies-arrayexpress

Aqueous and DMSO extracts from Annona muricata leaves protect from ferroptosis to both HT-1080 fibrosarcoma cells and HMEC-1 endothelial cells.

Project description:Graviola (Annona muricata) is a tropical plant with many traditional ethnobotanic uses and pharmacologic applications. A metabolomic study of both aqueous and DMSO extracts from Annona muricata leaves recently allowed us to identify dozens of bioactive compounds. In the present study, we use a proteomic study to reveal new bioactivities of these leave extracts on both conditioned media and extracts of HT-1080 fibrosarcoma treated cells. Our results reveal the complete sets of deregulated proteins after treatment with aqueous and DMSO extracts from An-nona muricata leaves. Functional enrichment analysis of proteomic data suggests deregulation of cell cycle and iron metabolism, which are experimentally validated. Additional experimental data reveal that these extracts protect from ferroptosis to both HT-1080 fibrosarcoma cells and HMEC-1 endothelial cells.

2023-10-24 | PXD042354 | Pride

SMAD2 binding regions in triple negative breast cancer cell line, Hs578T

Project description:Inhibitors for cyclin-dependent kinase (CDK) 4 and CDK6 have been established as effective therapeutic options for hormone receptor (HR)-positive, HER2-negative advanced breast cancer. Although the CDK4/6 inhibitors mainly target the cyclin D-CDK4/6-retinoblastoma tumor suppressor protein (RB) axis, little is known about clinical impact of inhibiting phosphorylation of other CDK4/6 target proteins. Here, we have focused on other CDK4/6 targets, SMAD proteins. We showed that a CDK4/6 inhibitor Palbociclib and Activin-SMAD2 signaling cooperatively inhibited cell cycle progression of a luminal-type breast cancer cell line T47D. Mechanistically, Palbociclib enhanced SMAD2 binding to the genome through inhibiting linker phosphorylation of the SMAD2 protein by CDK4/6. Comparison of the SMAD2 ChIP-seq data of T47D with those of a triple-negative breast cancer cell line Hs578T indicated that Palbociclib augments different SMAD2-mediated program defined based on types of cells, and enhances SMAD2 binding to the target regions on the genome without affecting its binding pattern. Collectively, the CDK4/6 inhibitor facilitates the cytostatic effects of Activin-SMAD2, while it also enhances its tumor promoting effects depending on types of breast cancer.

2018-10-23 | GSE117496 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data